joining Thank everyone, and call Good for you year was morning, Eagle. you, an our XXXX thank outstanding Lisa. today. for
expectations non-GAAP adjusted per earnings million non-GAAP in XXXX, share our in diluted earnings per best for XXXX, $X.XX and a previously $X.XX this the posted is end achievement at of diluted Our came non-GAAP with adjusted for EBITDA XXXX. full-year for This significant share adjusted $X.XX We non-GAAP compared year's was in full-year. the ’XX, diluted earned our per earnings company our $XXX in than more size. triples of share a last top very
‘XX, year. $XX.X The million was grew QX million share $X.XX quarter in QX diluted up with non-GAAP of in our fourth XXXX $XX income compared the of XX.X% to the earnings quarter ‘XX. from by of $X.XX, adjusted prior fourth non-GAAP per in Adjusted of net
tripled just share that expect strong XXXX. we in years the did per our It's not to earnings we have that how earnings per diluted Our we non-GAAP year-over-year adjusted continue few share in been to past and it.
accomplished mostly was this that again once out point me Let organically.
debt seven finances through any raised years. not equity have money or about in We
million and In this. ‘XX, BARHEMSYS, products two still combined since commercial through in BYFAVO acquire our about fact, and $XXX care shares its receivables share cash million, our buyback also to all for In $XXX program. XXXX acute we Eagle and we of almost net repurchase Acacia have stock spent to used after and Pharma we cash
held accounts. million is of equivalents And with at entirely cash outstanding and our credit in $XX.X JPMorgan. have operating almost we JPMorgan debt million $XXX cash Our facility on
position As small are of with than financial companies. less we shape, of assets $X strong individual Silicon very account in to today, in Valley not no hold but of places million or in we it at only excess us accounts a in number Bank good acquire $XXX,XXX
successfully profitability. has and managed Eagle strong expenses had
this a assuming earn We four-year ’XX, guidance, to to annual to non-GAAP of represent mid-range period this rate million of ‘XX would X%. $XX the XXXX growth million XXXX the compound $XX EBITDA in expect of of adjusted for
on important our an that At developing to need focused near-term. the for doubt we them. organization, this tried are will in who patients in we mindset the the have manner products creates I same keenly achieve time, profitability. change a As
discuss year. our Let's strength the of
reflects the buy our of XX% world. the both bendamustine of PEMFEXY margin and royalty Our our down fourth gross expiration quarter ‘XX
We ‘XX we XX% over the of February. point sales of just expect oncology. fourth and quarter a the with first we share already $XX to our be the X% the ‘XX. U.S. will that ‘XX, market had in quarter it impacts in of these previously XX% million doubling continue quarter have to community through in the to that end exited that we positive We anticipated share and I by captured net of out as continues stated expectation share of PEMFEXY
sales reached million, be sales $XX net of than PEMFEXY higher in ‘XX, net we PEMFEXY $XX million. will ‘XX that expect In
a in the royalties and for first $XX million on to on the in October beginning a ‘XX eliminate X royalty profits reduced exchange reduced million on $XX PEMFEXY thereafter. reminder, of profit As QX royalty we of of ‘XX, a for one-time payment future PEMFEXY
TREAKISYM me and net bendamustine BELRAPZO in bendamustine In had update and XX% of on revenues In thus Let revenue ‘XX. the franchise total, provide over in of speak XX%, far first BENDEKA our year-over-year our grew ‘XX. an while in we ‘XX, ‘XX now sales profitability declined. where to and growth are and quarter revenue we both respectively,
quarter December have obviously ‘XX. Eagle's competition many of weeks X those times faced strong discussed earnings competition include discussed three time we in first today for bendamustine of just fourth on December. reported As ‘XX and franchise that the
on XX% IQVIA about U.S. share. XX% February share of through Based and historically hold a held BENDEKA BELRAPZO market the two data have an where bendamustine XX, those products
will We TREANDA oncology compared continue maintain positions that to superior is to TREANDA, market healthcare share and continue and believe or throughout a meaningfully for providers, that BENDEKA ‘XX. product it to strong patients generic
saying erosion ‘XX. maintain for we some entered been to are up profit holding nearly of expectations. days to our BENDEKA BELRAPZO XX% and since our our competition the quite market, we've see approximately As support that XX in our gross we to time, can the compared to relative forecast In expect products well ’XX,
Let we that it of QX profits ‘XX point pay came obligation a me out of that no royalty longer products had the until expired also cap. in bendamustine XX% gross out royalty and our in lifetime a
products Turning BYFAVO. now to for Acacia BARHEMSYS and the
in Although two XXX,XXX ‘XX. in $X.X still of BYFAVO In ‘XX million the combined have BARHEMSYS for ’XX, base, on first of our small the products the Acacia's two in quarter sales is acquisition $X.X mind X and the by doubling QX net these of which of and we of and size sales our in million June the Acacia fully ‘XX sales represents second-half products by from closing reported team. that company in for nearly prior close. of billion the a Eagle a included $X.X full to of sales the Keep trained post second-half
continue. Both trends encouraged will extremely growth hopeful XXXX. until products the and are We protected patent are
in ’XX RYANODEX the sales sales two and Net generated our increased in combined ‘XX. of ‘XX year-over-year XX% full-year launches million vasopressin in net by new $XXX PEMFEXY for in
by all beyond of the the related manufacturing vasopressin the to inventory market ‘XX, During current discontinuing sales and decided quarter first levels. exit we halting
proudly is this record our our So ‘XX. opportunity to year in discuss
‘XX have in three products and and question everybody's and the Once pipeline believe pipeline commercial past, collectively mind seven are beyond? what is the strong as again, The with exciting product on we indicated market on programs. our we opportunities about
historical ‘XX would million second year represent an non-GAAP EBITDA our guidance to million Our adjusted non-GAAP of for $XX of ‘XX. in for to $XX record, EBITDA full-year adjusted record
past, ability we growth can accretive growth several we to the protected believe our in balance our of years us growth. an our huge and and market company impact cash to come. beyond make and for to this would long even Taking for but on would have way meaningful potentially as we ability successful. have it We're the a only on expect we accomplish acquisition not make for sheet. These dramatic If our to BYFAVO, our options. BARHEMSYS a towards many one solidify significant that we that desires objectives possibly future we ’XX, in for Eagle work believe could a treatment our being to go brings assets which the But offer value very This opportunities pipeline could patent are products, look on impact as selective, years. a additional positioning potential have Eagle Eagle size impact acquisition have belief have first-in-class while indicated potentially to
respiratory The significant developed in of for chemical of pipeline drug orphan an QX and depression, respiratory FDA by stimulant new granted the treatment apnea one-of-a-kind Enalare drug prematurity opportunities include entity. which potential community for being postoperative ENA-XXX, It overdose of is an agnostic investigational designation ‘XX.
two equity Enalare XX% upfront in an rest Enalare paid we to event in ‘XX reminder, February the August purchase exchange acquired a achieved. stake option and investments And milestones in As the of specified an for are a of in we have ‘XX. approximately of
pneumonia approval centers supraventricular FDA and landiolol NDA a a with severe patients patients atrial the local flutter. including ventricular review. study and Phase CALXX, expected And filing for for in tachycardia, XX expected of countries. seeks treatment is community-acquired rate landiolol for in our broad-spectrum with bacterial for is agent The XXX novel reduction short-term atrial under for first-in-class XXX fibrillation which anti-virulence underway the X a
about to We year a on readouts in so. data CALXX Enalare or have expect informative and
In of does of that we This we through ENA-XXX million to required not ‘XX, any projected event or remaining the that be exercise $XX.X shares combined. and that meantime Enalare, an option would in certain about million Enalare. expense cash $XX.X achieve milestones the CALXX equity cash purchase investment for use to to to Enalare additional are through the our support in R&D include
two see this diversified meet As avenues we clinical company, open we pharmaceutical a to acquisitions. goal: into us development to and transition
plan not now, additional to make carries potentially development higher extremely money Pharma that with Acacia succeed and the clear, hope concentrate we then required we but on if a spent and with recognize spent. risk, acquisition. the programs, acquisitions. do add clinical we more any be balance We our For and clinical company and to CALXX an we investment will To we both accompanying believe to earnings be successful, on development have cash the If we well then Enalare would back to are intend return.
In summary [landiolol, strong we year the and meaningful shaping (ph) a ‘XX be the hard and ‘XX ENA-XXX BYFAVO, turn hope see to on out. next was to Eagle, advancing year. of on We year work believe or very for make an BARHEMSYS those how development support focus outstanding efforts so acquisition, to our up and over another is CALXX] and
to Well, Cahill our Brian with I'll that, financials. Brian? full-year quarter turn the fourth and over to call discuss
